WO2002044344A3 - Basal cell carcinoma cultures, methods related thereto and their use - Google Patents

Basal cell carcinoma cultures, methods related thereto and their use Download PDF

Info

Publication number
WO2002044344A3
WO2002044344A3 PCT/US2001/044457 US0144457W WO0244344A3 WO 2002044344 A3 WO2002044344 A3 WO 2002044344A3 US 0144457 W US0144457 W US 0144457W WO 0244344 A3 WO0244344 A3 WO 0244344A3
Authority
WO
WIPO (PCT)
Prior art keywords
basal cell
cultures
cell carcinoma
methods
methods related
Prior art date
Application number
PCT/US2001/044457
Other languages
French (fr)
Other versions
WO2002044344A2 (en
Inventor
Allison P Berg
Carmen Pepicelli
Frank Wang
Original Assignee
Curis Inc
Allison P Berg
Carmen Pepicelli
Frank Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc, Allison P Berg, Carmen Pepicelli, Frank Wang filed Critical Curis Inc
Priority to AU2002217911A priority Critical patent/AU2002217911A1/en
Publication of WO2002044344A2 publication Critical patent/WO2002044344A2/en
Publication of WO2002044344A3 publication Critical patent/WO2002044344A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C12N5/0698—Skin equivalents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/04—Screening or testing on artificial tissues
    • C12N2503/06—Screening or testing on artificial skin

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the discovery of methods for culturing basal cell carcinomas. In one aspect the invention provides basal cell carcinoma cultures. In other aspects, the invention provides media, screening assays and methods for making BCC cultures. The cultures, media, assays and methods of the invention will be useful, in part, for finding BCC therapeutics and allowing more sophisticated in vitro studies of BCCs.
PCT/US2001/044457 2000-11-28 2001-11-28 Basal cell carcinoma cultures, methods related thereto and their use WO2002044344A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002217911A AU2002217911A1 (en) 2000-11-28 2001-11-28 Basal cell carcinoma cultures, methods related thereto and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25366000P 2000-11-28 2000-11-28
US60/253,660 2000-11-28

Publications (2)

Publication Number Publication Date
WO2002044344A2 WO2002044344A2 (en) 2002-06-06
WO2002044344A3 true WO2002044344A3 (en) 2003-02-20

Family

ID=22961187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044457 WO2002044344A2 (en) 2000-11-28 2001-11-28 Basal cell carcinoma cultures, methods related thereto and their use

Country Status (2)

Country Link
AU (1) AU2002217911A1 (en)
WO (1) WO2002044344A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5435946B2 (en) 2005-08-22 2014-03-05 ジョンズ ホプキンス ユニバーシティ Hedgehog pathway antagonists for treating diseases
BR112019020953A2 (en) 2017-04-05 2020-05-05 Yeda Res & Dev ex vivo culture system and methods of using it
IL257225A (en) 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
WO2022259242A1 (en) 2021-06-06 2022-12-15 Yeda Research And Development Co. Ltd. Combined treatment for cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027135A2 (en) * 1999-10-13 2001-04-19 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
WO2002036818A2 (en) * 2000-11-02 2002-05-10 Consejo Superior De Investigaciones Cientificas Method for detecting inhibitors of tumour growth

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027135A2 (en) * 1999-10-13 2001-04-19 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
WO2002036818A2 (en) * 2000-11-02 2002-05-10 Consejo Superior De Investigaciones Cientificas Method for detecting inhibitors of tumour growth

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOOTH DANIEL R: "The hedgehog signalling pathway and its role in basal cell carcinoma.", CANCER AND METASTASIS REVIEWS, vol. 18, no. 2, 1999, pages 261 - 284, XP001106381, ISSN: 0167-7659 *
BRYSK M M ET AL: "CULTURE OF BASAL CELL CARCINOMA", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 98, no. 1, 1992, pages 45 - 49, XP001106714, ISSN: 0022-202X *
DAHMANE N ET AL: "Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumors", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 389, 23 October 1997 (1997-10-23), pages 876 - 881, XP002133796, ISSN: 0028-0836 *
FAN HONGRAN ET AL: "Induction of basal cell carcinoma features in transgenic human skin expressing sonic hedgehog.", NATURE MEDICINE, vol. 3, no. 7, 1997, pages 788 - 792, XP001105578, ISSN: 1078-8956 *
GRANDO SERGEI A ET AL: "Nodular basal cell carcinoma in vivo vs in vitro: Establishment of pure cell cultures, cytomorphologic characteristics, ultrastructure, immunophenotype, biosynthetic activities, and generation of antisera.", ARCHIVES OF DERMATOLOGY, vol. 132, no. 10, 1996, pages 1185 - 1193, XP001106709, ISSN: 0003-987X *

Also Published As

Publication number Publication date
WO2002044344A2 (en) 2002-06-06
AU2002217911A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
AU2002258477A1 (en) Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture
EP3486314A3 (en) Placental stem cell populations
EP1360314A4 (en) Chemically defined medium for cultured mammalian cells
MY148759A (en) Methods to culture circovirus
EP1483281A4 (en) Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules
MXPA01008465A (en) Biotinylated-chemokine antibody complexes.
WO2006127809A3 (en) Methods for expansion and analysis of cultured hematopoietic stem cells
WO2001021760A3 (en) Cell culture spinner flasks
NZ569543A (en) Means and methods for influencing the stability of antibody producing cells
WO2008060541A3 (en) In vitro expansion of postpartum-derived cells using microcarriers
SG152273A1 (en) Pdx1 expressing endoderm
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
WO2005120090A3 (en) In vitro techniques for use with stem cells
WO2005094353A3 (en) Methods for production of regulatory t cells and uses thereof
WO2003044045A3 (en) Peptides promoting cell adherence, growth and secretion
ATE465637T1 (en) CYSTEINE GRANULES AND THEIR USE AS GROWTH STIMULANTS FOR BIFIDOBACETERIUM ANIMALIS LACTIS
WO2002044344A3 (en) Basal cell carcinoma cultures, methods related thereto and their use
WO2005089102A3 (en) Methods of refolding mammalian glycosyltransferases
WO2003034025A3 (en) Methods and reagents for improved cell-based assays
SI1456238T1 (en) Production of f(ab')2 fragments in mammalian cells
AU2001281859A1 (en) Immobilising carrier comprising a porous medium
DE602006014534D1 (en) PREPARATION AND USE OF BASAL MEMBRANE PARTICLES
WO2007005611A3 (en) Progenitor cells and uses thereof
DE60330223D1 (en)
AU2698197A (en) Interaction of cyclin d1 and estrogen receptor and its use in assays

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP